Cargando…

The Effect of a Histone Deacetylase Inhibitor (AR-42) and Zoledronic Acid on Adult T-Cell Leukemia/Lymphoma Osteolytic Bone Tumors

SIMPLE SUMMARY: Adult T-cell leukemia (ATL) Leukemia is an aggressive, peripheral blood (T-cell) neoplasm associated with human T-cell leukemia virus type 1 (HTLV-1) infection. Recent studies have implicated dysregulated histone deacetylases in ATL pathogenesis. ATL modulates the bone microenvironme...

Descripción completa

Detalles Bibliográficos
Autores principales:	Elshafae, Said M., Kohart, Nicole A., Breitbach, Justin T., Hildreth, Blake E., Rosol, Thomas J.
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	MDPI 2021
Materias:	Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8533796/ https://www.ncbi.nlm.nih.gov/pubmed/34680215 http://dx.doi.org/10.3390/cancers13205066

Ejemplares similares

Animal Models of Cancer-Associated Hypercalcemia
por: Kohart, Nicole A., et al.
Publicado: (2017)

Mouse model recapitulates the phenotypic heterogeneity of human adult T-cell leukemia/lymphoma in bone
por: Kohart, Nicole A., et al.
Publicado: (2019)

Selective Activity of the Histone Deacetylase Inhibitor AR-42 against Leukemia Stem Cells: A Novel Potential Strategy in Acute Myelogenous Leukemia
por: Guzman, Monica L., et al.
Publicado: (2014)

Histone deacetylase inhibitor AR-42 and achiral analogues kill malaria parasites in vitro and in mice
por: Chua, Ming Jang, et al.
Publicado: (2021)

Effect of Dickkopf-1 (Dkk-1) and SP600125, a JNK Inhibitor, on Wnt Signaling in Canine Prostate Cancer Growth and Bone Metastases
por: Supsavhad, Wachiraphan, et al.
Publicado: (2021)

Novel histone deacetylase inhibitor AR-42 exhibits antitumor activity in pancreatic cancer cells by affecting multiple biochemical pathways
por: Chen, Yi-Jin, et al.
Publicado: (2017)

HTLV-1 viral oncogene HBZ induces osteolytic bone disease in transgenic mice
por: Esser, Alison K., et al.
Publicado: (2017)

A Novel Histone Deacetylase Inhibitor, AR-42, Reactivates HIV-1 from Chronically and Latently Infected CD4(+) T-cells
por: Mates, Jessica M., et al.
Publicado: (2015)

Suppression of Tumor Growth and Muscle Wasting in a Transgenic Mouse Model of Pancreatic Cancer by the Novel Histone Deacetylase Inhibitor AR-42()()
por: Henderson, Sally E., et al.
Publicado: (2016)

Early phase clinical studies of AR‐42, a histone deacetylase inhibitor, for neurofibromatosis type 2‐associated vestibular schwannomas and meningiomas
por: Welling, D. Bradley, et al.
Publicado: (2021)

Histone deacetylase inhibitors in Hodgkin lymphoma
por: Buglio, Daniela, et al.
Publicado: (2010)

High affinity zoledronate-based metal complex nanocrystals to potentially treat osteolytic metastases
por: Quiñones Vélez, Gabriel, et al.
Publicado: (2022)

On atmospheric $^{39}Ar$ and $^{42}Ar$ abundance
por: Cennini, P, et al.
Publicado: (1995)

Histone Deacetylases and Histone Deacetylase Inhibitors in Neuroblastoma
por: Phimmachanh, Monica, et al.
Publicado: (2020)

Histone Deacetylase Inhibition: An Important Mechanism in the Treatment of Lymphoma
por: Guo, Shan-qi, et al.
Publicado: (2012)

Antiandrogen-Equipped Histone Deacetylase Inhibitors Selectively Inhibit Androgen Receptor (AR) and AR-Splice Variant (AR-SV) in Castration-Resistant Prostate Cancer (CRPC)
por: Chandrasekaran, Balaji, et al.
Publicado: (2023)

The Novel Deacetylase Inhibitor AR-42 Demonstrates Pre-Clinical Activity in B-Cell Malignancies In Vitro and In Vivo
por: Lucas, David M., et al.
Publicado: (2010)

Remarkable Regression of an Osteolytic Lesion of Large Cell Lung Cancer Treated with Zoledronic Acid: A Case Report
por: Kawai, Sadayuki, et al.
Publicado: (2012)

Histone Deacetylases (HDACs) Guided Novel Therapies for T-cell lymphomas
por: Zhang, Qing, et al.
Publicado: (2019)

Update on histone deacetylase inhibitors in peripheral T-cell lymphoma (PTCL)
por: Lu, Guang, et al.
Publicado: (2023)

Histone deacetylase 9 regulates breast cancer cell proliferation and the response to histone deacetylase inhibitors
por: Lapierre, Marion, et al.
Publicado: (2016)

Roles of Histone Deacetylases in Acute Myeloid Leukemia With Fusion Proteins
por: Zhang, Juan, et al.
Publicado: (2021)

Histone deacetylase inhibitor potentiated the ability of MTOR inhibitor to induce autophagic cell death in Burkitt leukemia/lymphoma
por: Dong, Li Hua, et al.
Publicado: (2013)

Epigenetic therapies in acute myeloid leukemia: the role of hypomethylating agents, histone deacetylase inhibitors and the combination of hypomethylating agents with histone deacetylase inhibitors
por: Xu, Qing-Yu, et al.
Publicado: (2020)

Beyond Histone and Deacetylase: An Overview of Cytoplasmic Histone Deacetylases and Their Nonhistone Substrates
por: Yao, Ya-Li, et al.
Publicado: (2011)

Enhancement of Vaccinia Virus Based Oncolysis with Histone Deacetylase Inhibitors
por: MacTavish, Heather, et al.
Publicado: (2010)

The histone deacetylase Hos2 forms an Hsp42-dependent cytoplasmic granule in quiescent yeast cells
por: Liu, I-Chun, et al.
Publicado: (2012)

Histone deacetylase 6 activity is critical for the metastasis of Burkitt’s lymphoma cells
por: Ding, Ning, et al.
Publicado: (2014)

Histone deacetylase inhibitors induce apoptosis in myeloid leukemia by suppressing autophagy
por: Stankov, Metodi V., et al.
Publicado: (2013)

Histone Deacetylases and Histone Deacetylase Inhibitors: Molecular Mechanisms of Action in Various Cancers
por: Sanaei, Masumeh, et al.
Publicado: (2019)

Inhibition of Histone Deacetylase 3 Causes Replication Stress in Cutaneous T Cell Lymphoma
por: Wells, Christina E., et al.
Publicado: (2013)

Recalcitrant Subcutaneous Panniculitis-Like T-Cell Lymphoma Responsive to Histone Deacetylase Inhibitor
por: Gleason, Laura, et al.
Publicado: (2022)

Chemical Phylogenetics of Histone Deacetylases
por: Bradner, James E., et al.
Publicado: (2010)

Histone deacetylases in viral infections
por: Herbein, Georges, et al.
Publicado: (2010)

Butyrate Histone Deacetylase Inhibitors
por: Steliou, Kosta, et al.
Publicado: (2012)

Histone deacetylase signaling in cardioprotection
por: Lehmann, Lorenz H., et al.
Publicado: (2013)

Histone deacetylase 6 in cancer
por: Li, Ting, et al.
Publicado: (2018)

Oral histone deacetylase inhibitor tucidinostat (HBI‐8000) in patients with relapsed or refractory adult T‐cell leukemia/lymphoma: Phase IIb results
por: Utsunomiya, Atae, et al.
Publicado: (2022)

Histone deacetylase inhibitors suppress mutant p53 transcription via histone deacetylase 8
por: Yan, Wensheng, et al.
Publicado: (2012)

Expression of Histone Deacetylases in Diffuse Large B-cell Lymphoma and Its Clinical Significance
por: Lee, Sung Hak, et al.
Publicado: (2014)

Cannot write session to /tmp/vufind_sessions/sess_vffr6jf74s4o7gfhn2tgbvtnn8